A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications (Q35122255)

6 August 2017

1 reference

title

A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications (English)

1 reference

6 August 2017

1 reference

Vito Michele Lauta

1

1 reference

PubMed ID

12733143

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

2440-2452

1 reference

6 August 2017

10

1 reference

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Molecular alterations of IL-6R, lck and c-myc genes in transforming monoclonal gammopathies of undetermined significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Interleukin-6 serum levels in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Preparing the ground for vaccination against multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Interferon and multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Ma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11072

7 January 2021

Identifiers

DOI

10.1002/CNCR.11072

1 reference

6 August 2017

1 reference

PubMed ID

12733143